PT  - JOURNAL ARTICLE
AU  - ZORICA VESOVIC
AU  - KATHLEEN HERKOMMER
AU  - WALTHER VOGEL
AU  - THOMAS PAISS
AU  - CHRISTIANE MAIER
TI  - Role of a <em>CYP17</em> Promoter Polymorphism for Familial Prostate Cancer Risk in Germany
DP  - 2005 Mar 01
TA  - Anticancer Research
PG  - 1303--1307
VI  - 25
IP  - 2B
4099  - http://ar.iiarjournals.org/content/25/2B/1303.short
4100  - http://ar.iiarjournals.org/content/25/2B/1303.full
SO  - Anticancer Res2005 Mar 01; 25
AB  - Background: A thymidine to cytosine transition (designated A2 variant) in the promoter region of CYP17 has previously been associated with a familial history of prostate cancer in North American families. The purpose of the present study was to determine whether this correlation could be replicated in a European population. Materials and Methods: Case-control comparisons were performed by modelling a dominant (A1/A2 + A2/A2 vs. A1/A1) and a recessive (A2/A2 vs. A1/A2 + A1/A1) effect of the promoter modification. Results: An insignificant overrepresentation of homozygous carriers of the A2 allele (recessive effect) was found in sporadic cases, as compared to controls. However, the A2 variant was not related to familial disease. Conclusion: Our results do not suggest a role of CYP17 as a high-risk susceptibility gene for familial prostate cancer, nor as a modifier for the disease risk in the European population. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved